Actuate Therapeutics financials
$0.6860−6.82%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY10 Jun 30 |
|---|---|---|---|
| Revenue | $0.00 | $0.00 | $29.9M |
| Gross profit | $0.00 | $0.00 | $20.2M |
| Gross margin | — | — | 67.5% |
| Operating income | -$22.5M | -$25.2M | $1.2M |
| Net income | -$22.2M | -$27.3M | -$127.0K |
| Net margin | — | — | −0.4% |
| Diluted EPS | $-1.06 | $-3.26 | $-0.01 |
| EBITDA | -$22.5M | -$25.2M | $1.9M |
| Operating cash flow | -$19.2M | -$21.8M | $2.5M |
| Free cash flow | -$19.2M | -$21.8M | $2.0M |
| Diluted shares | 21.0M | 8.4M | 22.2M |
Balance sheet
| Period end | Dec 31 | Dec 31 |
|---|---|---|
| Cash & equivalents | $13.2M | $8.6M |
| Short-term investments | $0.00 | $0.00 |
| Total debt | $27.0K | $71.0K |
| Total assets | $14.0M | $9.3M |
| Total liabilities | $6.1M | $9.2M |
| Shareholders' equity | $7.9M | $104.2K |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology